CA-YOKOGAWA-ELECTRIC
25.3.2022 06:02:12 CET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that it has successfully completed a proof of concept test of technology that reduces energy consumption and stabilizes the quality of the water discharged by the Tapia Water Reclamation Facility of the Las Virgenes Municipal Water District (LVMWD), located in Los Angeles County, California. This initiative was undertaken as part of the company’s proposal to improve the performance of existing wastewater reclamation facilities in conjunction with a program sponsored by the Japan Ministry of Economy, Trade and Industry that seeks to examine opportunities for the overseas deployment of high quality energy infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324006055/en/
Water stress is an increasingly pressing issue worldwide due to the effects of climate change and the rising demand for water driven by population growth. In order to ensure stability in water resources, more and more countries are looking to make proactive use of reclaimed water. In the USA, the state of California is considering changes in regulations*1 that will allow the direct use of reclaimed water for drinking water by the end of 2023, and this is the subject of serious discussions and cooperation between the public and private sectors.
This proof of concept was conducted as part of the Pure Water Project and led by the LVMWD, whose aim is to produce potable water from highly treated wastewater in compliance with State water quality standards. Doing so required LVMWD to consider alternative technological approaches, as treating water to potable quality consumes enormous amounts of electricity and is more maintenance intensive. Yokogawa has been studying ways to address such challenges by making use of the company’s extensive process knowledge and experience in monitoring and control of industrial facilities.
Given the large fluctuations in the quality of the wastewater that flows into reclamation facilities, plant operators must take proper care while monitoring the inflow rate to ensure that the mandated water quality standards are met, and rely on their knowledge and technical expertise to make the necessary adjustments. Yokogawa applied its advanced data driven modeling for optimization (DDMO) software suite to model and then predict setpoints to optimize operations and support operator decision making while maintaining the targeted water quality at water treatment facilities.
As this proof of concept was conducted during the COVID-19 pandemic, Yokogawa used its Yokogawa Cloud platform to minimize the site activities and move site data to Japan where the DDMO software utilized real-time operational data to derive control setpoints that were sent back to operators at the Tapia Water Reclamation Facility. After conducting a multifaceted evaluation and performing a concrete verification of effectiveness, it was revealed that improvements in operational efficiency had yielded an over 10% reduction in power consumption, while meeting all water quality standards. Impressed with these results, the WateReuse Association presented Yokogawa and its partners with a 2022 Transformational Innovation award*2 .
Tsuyoshi Abe, a Yokogawa Electric vice president and head of the Marketing Headquarters, says, “Water is a public asset and a finite resource. Goal 6 of the SDGs is to ‘Ensure access to water and sanitation for all,’ and this is an important area where Yokogawa can contribute. Toward this end, the effective utilization of reclaimed water as a sustainable water source for communities is a groundbreaking approach. The efficient purification and provision of safe and secure drinking water requires the understanding of all stakeholders and a lot of revolutionary technology. In order to build a circular ecosystem for water resources and create new value, we will work to further strengthen our collaboration with partners to drive forward co-innovation, and utilizing our capabilities to measure and connect, we will fulfill our responsibilities for the future of our planet.”
*1 The California Water Boards: Regulating direct potable reuse in California
https://www.waterboards.ca.gov/drinking_water/certlic/drinkingwater/direct_potable_reuse.html
*2 WateReuse Awards for Excellence, Transformational Innovation award, presented at the 37th Annual WateReuse Symposium. Award recipients: Yokogawa Electric Corporation, Las Virgenes Municipal Water District, Carollo Engineers, the National Water Research Institute, Metropolitan Water District, Bureau of Reclamation, IOSight
https://watereuse.org/news-events/awards/past-award-winners/watereuse-award-winners-2022/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324006055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom